Michael Lincoln, MD
Cardiovascular Disease · Silver Spring, MDNPI 1376593566
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (40.3%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 75.7% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2022 at $5,512 and has fallen 92.4% since, to $420 in 2025.
Across 246 payments — averaging $57.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$11K
- Novartis$578
- Amgen$505
- Johnson & Johnson$382
- Merck$254
- Amarin Pharma, Inc.$185
- plus $2K from 28 others
Across 55 payments — averaging $1360.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$75K
What the payments were for
- Speaking & faculty fees$3,77927%
- Travel & lodging$4,62733%
- Food & beverage$5,72940%
- Education$190%
- Other$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 74 | $10,767 |
| Novartis | 27 | $578 |
| Amgen | 26 | $505 |
| Johnson & Johnson | 24 | $382 |
| Merck | 12 | $254 |
| Amarin Pharma, Inc. | 10 | $185 |
| Boston Scientific | 7 | $174 |
| AstraZeneca | 8 | $145 |
| Inspire Medical Systems, Inc. | 2 | $122 |
| Boehringer Ingelheim | 5 | $120 |
| Pfizer | 6 | $98 |
| E.r. Squibb & Sons, L.L.C. | 5 | $90 |
| Philips North America LLC | 4 | $77 |
| Baxter Healthcare | 3 | $73 |
| Esperion Therapeutics, Inc. | 4 | $64 |
| Alnylam Pharmaceuticals Inc. | 2 | $54 |
| Novo Nordisk | 2 | $51 |
| Lundbeck LLC | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Abbott | 2 | $39 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $35 |
| Medicomp Inc | 2 | $34 |
| Welch Allyn | 1 | $34 |
| Bardy Diagnostics, Inc. | 2 | $29 |
| Elutia, Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Biotronik Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| AbbVie | 1 | $14 |
| Edwards Lifesciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,872
- AZURE XT DR MRI SURESCAN$121
How this compares
$14,221 in reported general payments places this provider in the 85th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 176 | $253,403 |
| XareltoRivaroxaban | 91 | $106,491 |
| EntrestoSacubitril/Valsartan | 41 | $71,473 |
| Metoprolol Succinate | 299 | $5,504 |
| Digoxin | 54 | $4,469 |
| Ezetimibe | 43 | $3,429 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 14 | $2,338 |
| Atorvastatin Calcium | 238 | $2,159 |
| Amiodarone Hcl | 52 | $1,881 |
| Losartan Potassium | 142 | $1,503 |
| Bumetanide | 24 | $1,050 |
| ClopidogrelClopidogrel Bisulfate | 89 | $1,043 |
| Irbesartan | 14 | $999 |
| Carvedilol | 101 | $838 |
| Furosemide | 78 | $719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $98 | $253,403176 claims |
| Johnson & JohnsonXarelto | $382 | $106,49191 claims |
| NovartisEntresto | $578 | $71,47341 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Silver Spring
- Ellis UngerSilver Spring$23K
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Allen TaylorN Bethesda$456K
- David GoorayLargo$333K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Mark HaigneyBethesda$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.